Articles by SeekingAlpha

A Definitive Guide to China ETFs

Michael Johnston submits: By Jared Cummans Historically, many investors have maintained only minimal exposure to emerging markets equities, citing the significant... Read >>

The Problem With Rosie and Inflation

Econophile submits: Before I start I wish to say that I highly respect David Rosenberg at Gluskin Sheff, one of the few mainstream economists to call the crash, and whose observations... Read >>

No Surprises in the Fed Beige Book

Michael Shulman submits: The only surprising thing about the Fed beige book report is the surprise expressed by many on Wall Street. ... Read >>

8 More Reasons Why a Double Dip Is Coming

Daryl Montgomery submits: As earnings season continues and one company after another beats expectations, the economic numbers are continuing to come in below estimates. The data and... Read >>

Second Quarter Earnings Season Beat Rate

Hickey and Walters ( Bespoke ) submit: lt may seem like earnings season has been going on forever now, but we're actually just about a third of the way through. Through yesterday, 662 US... Read >>

After the European Bank Stress Tests

Alicia Damley submits: Underwhelming might be the best way to describe the results of the European bank stress tests and the market's reaction to them. Paying heed to market demands, the... Read >>

Rethinking AGG: One-Stop Fixed-Income Exposure?

Michael Johnston submits: The last year has seen a tremendous amount of innovation in the fixed income ETF space. iShares debuted a line of "target end date" municipal... Read >>

Slowdown or Double Dip? A Little Clarity on the ECRI WLI

Prieur du Plessis submits: A significant number of pundits focus on the ECRI* Weekly Leading Index (( WLI )) in their quest to make sense of the stock market's most likely direction,... Read >>

New Home Sales: Still at Depression Levels

Daryl Montgomery submits: The June New Homes Sales figures were released today and the Commerce Department claimed they were up almost 24%. Stocks rallied strongly on the supposedly good... Read >>

Will MannKind's Afrezza Succeed Where Pfizer's Exubera Failed?

Rockford Coscia submits: This December, Afrezza, MannKind's ( MNKD ) inhalable insulin therapy for prandial (meal-time) management of blood glucose in diabetics, faces FDA decision.... Read >>

Displaying 1491-1500 of 2367
<< first < previous 150 151 152 153 154 200 next > last >>